Physician
Hematology
Dr. Michele L. Basche, MD
|
|
Give Review
Michele Basche practices Hematology. She studied medicine at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical university. University of California San Francisco School of Medicine is ranked 3/3 in Research/PrimaryCare. She received awards:"Meaningful Use Stage 1 Certification". Doctor Michele L. Basche, MD is a published doctor. She has 13 papers published. The most current publication "Barriers to enrollment of elderly adults in early-phase cancer clinical trials." She is registered with Medicare.
Publications
- Re: Tumor characteristics and clinical outcome of elderly women with breast cancer.
- Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients w...
- A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in...
- Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
- Barriers to enrollment of elderly adults in early-phase cancer clinical trials.
- A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
- A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
- A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemci...
- A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
- Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
- A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
- Treatment of non-small-cell lung cancer in older persons.
Schools
University Of California San Francisco
University Of Colorado
University Of Colorado Health Sciences Center
Procedures Preformed
- Breast Cancer Treatment
- Cancer Counseling
- Cancer Pain Management
- Cancer Treatment
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
University of California San Francisco School of Medicine
Hospital
-
Sky Ridge Medical Center
Drug Facts
| NPI NUMBER | 1306820022 | |
| NPPES Provider LastName | BASCHE | |
| NPPES Provider FirstName | MICHELE | |
| NPPES Provider ZIPCode | 802181234 | |
| NPPES Provider State | CO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1129.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 71.0 | |
| Percent Opioid Claims | 6.29 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306820022 |
| Last Name Of The Provider | BASCHE |
| First Name Of The Provider | MICHELE |
| View All |
Similar Doctors
|
Dr. Robert M. Rifkin, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Keren B. Sturtz, MD |
|
Dr. Scot M. Sedlacek, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Douglas M. Reznick, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stephen E. Howe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael T. Parra, MD |
|
|
Dr. Scott A. Kono, DO |
|
Dr. Charles A. Mateskon, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ioana M. Hinshaw, MD
This Doctor is OpenDoctor Recommended.
|